HPTN 083
Cabotegravir for HIV Prevention in MSM and Transgender Women
Paciente / Población Intervención / Exposición Comparación Desenlace
In 4,566 cisgender MSM and transgender women at high risk of HIV, long-acting injectable cabotegravir every 8 weeks reduced HIV acquisition compared with daily oral TDF/FTC.
N
4566
Diseño
Double-blind, double-dummy RCT
Desenlace
Incident HIV infection
Relevancia
2
ResultadoIncidence 0.41 vs 1.22 per 100 person-years; HR 0.34 — 66 % more effective.
Landovitz RJ, et al. N Engl J Med. 2021;385(7):595-608. 10.1056/NEJMoa2101016
Discusión y crítica
Basis of the FDA approval of long-acting cabotegravir for PrEP — particularly impactful for populations with adherence challenges.